Q32 Bio Inc (QTTB)

Q32 Bio has experienced several stock-impacting events in the past six months. These include participation in healthcare conferences, reporting fourth quarter 2025 financial results, announcing a $10.5 million registered direct offering, and the sale of ADX-097 to Akebia Therapeutics, Inc., which caused a significant surge in QTTB stock. The company also reported third quarter 2025 financial results and completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial. Additionally, the board exercised its discretion to reprice stock options.

Q32 Bio's products do not exhibit traditional demand seasonality. The demand for bempikibart is reflected in the strong patient interest and enrollment in its clinical trials, as demonstrated by the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial and the initiation of an open-label extension based on patient demand.

Q32 Bio, Inc. is a clinical-stage biotechnology company focused on developing novel biologic therapeutics for autoimmune and inflammatory diseases. Their lead product candidate is bempikibart (ADX-914), a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function. The company previously sold ADX-097 to Akebia Therapeutics, Inc. to focus on advancing bempikibart.

Q32 Bio, Inc. is headquartered in Waltham, Massachusetts, United States. Its common stock is listed on The Nasdaq Capital Market (NasdaqCM) under the ticker symbol QTTB, as well as on the Deutsche Boerse AG (DB) and the London Stock Exchange (LSE).

Q32 Bio's brand reputation has been influenced by the stock option repricing, which is considered a governance and reputational risk. The sale of ADX-097 led to a stock surge but also generated mixed reactions on social media. These events have impacted the company's brand image.

Q32 Bio Inc. has 54 institutional owners and shareholders holding a total of 8,043,910 shares. Major institutional owners include Orbimed Advisors Llc, Atlas Venture Life Science Advisors, LLC, and Carlyle Group Inc. Insider ownership stands at 1.8%, with recent sales by the CEO, CFO and President, and Chief Scientific Officer.